Dapagliflozin 10 MG [Farxiga] ( DrugBank: Dapagliflozin )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	1
88	Chronic thromboembolic pulmonary hypertension	1

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179356 (ClinicalTrials.gov)	January 1, 2023	16/12/2021	Dapagliflozin in Pulmonary Arterial Hypertension	Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial)	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo	Mads Ersbøll	NULL	Not yet recruiting	18 Years	N/A	All	52	Phase 2	NULL

88. Chronic thromboembolic pulmonary hypertension

---

Clinical trials : 157 /  Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179356 (ClinicalTrials.gov)	January 1, 2023	16/12/2021	Dapagliflozin in Pulmonary Arterial Hypertension	Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial Hypertension: A Double Blind Randomized Trial. (DAPAH-trial)	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo	Mads Ersbøll	NULL	Not yet recruiting	18 Years	N/A	All	52	Phase 2	NULL